China Biotech Services Holdings Ltd (08037) has released its interim results for the six months ended June 30, 2026, showing a substantial financial turnaround that has captured market attention.

The group recorded total revenue of HK$37.226 million, representing a robust increase of 49.71% compared to the same period last year. More notably, the company reported a profit attributable to shareholders of HK$18.23 million, achieving a significant swing from a loss position in the prior corresponding period to profitability this year. Earnings per share came in at HK$0.03.

According to the company's announcement, the surge in revenue was primarily driven by operations at its Pengbo (Hainan) Boron Neutron Capture Therapy Center, which commenced trial operations in February 2026. The facility contributed approximately HK$26.7 million in revenue from the provision of boron neutron capture therapy services, marking a key milestone in the group's strategic expansion into advanced cancer treatment technologies.